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Proteins are defined by a hierarchy of structural complexity that is founded on their primary amino acid sequence. Local and long-range intramolecular interactions among backbone and 
side-chain atoms determine higher-order folding behaviour by facil-
itating the formation of secondary structures and their arrangement 
into tertiary structure (Fig. 1a)1. Protein folds have evolved to mani-
fest varied and unique functional characteristics that are central 
to biological systems. The mimicry of protein structure and func-
tion represents a long-standing challenge to chemists and has been 
approached with artificial agents of varying size and complexity 
(Fig. 1b). At one end of this hierarchy are molecules intended to rec-
reate features of a few amino acids or isolated secondary structure 
— generally referred to as peptidomimetics2,3. Early examples of pep-
tidomimetics include mimics of primary structures found in small 
peptide hormones and peptide substrates of protease enzymes2. The 
latter were developed as inhibitors of protease function, and clini-
cal use of these compounds revolutionized the treatment of diseases 
such as HIV and hepatitis C4. Later, the stabilization or recreation 
of secondary structure in the absence of a protein context became 
a central focus of endeavours towards peptidomimetics. The chal-
lenges inherent to the mimicry of these more complex folded 
structures led to the invention of a number of distinct approaches, 
including peptides containing artificial building blocks, macrocyclic 
agents and entirely artificial backbones with defined folding pro-
pensities (Fig. 1b)3,5,6. Over the past decade, peptidomimetics have 
become valuable bioactive agents and drug candidates of particular 
utility in targeting the extended and flat biomacromolecular sur-
faces involved in protein–protein interactions7.
Building on the above precedent on peptidomimetics, there has 
been a recent growing interest in the design of artificial agents that 
mimic larger and more complex tertiary folds. While a daunting 
challenge, efforts along these lines have been enabled by advances in 
methodology for protein chemical synthesis8 and bioconjugation9 as 
well as the emergence of powerful protein-engineering approaches, 
including directed evolution10, computational design11 and non-
canonical amino acid mutagenesis12. A critical mass of results now 
suggests a burgeoning field of proteomimetics that are conceptually 
linked to, yet distinct from, their smaller peptidomimetic counter-
parts. The term proteomimetic has found limited previous use in 
the literature, primarily to describe molecules that recreate isolated 
segments of protein secondary structure5,13,14. Herein, we propose a 
definition of proteomimetics as molecules that have a defined ter-
tiary fold and recreate certain features of a protein, such as shape, 
recognition properties or enzymatic activity. In this Perspective, 
we highlight recent advances towards proteomimetic structures 
based on a classification of these agents into one of three catego-
ries (Fig. 1b). Most examples of proteomimetics reported to date 
were obtained by chemical protein engineering, an approach that 
can provide protein-like molecules with altered chain topology and/
or partially artificial backbone composition introduced in a chain 
composed mainly of natural amino acids. Other work has addressed 
the challenge of proteomimetic design by applying non-natural 
building blocks to construct completely artificial backbones able to 
adopt large, complex folds.
Altered chain topology
In natural proteins, the linear topology of the main chain is often 
altered by disulfide bridges formed between two cysteines spatially 
aligned in the folded state but distant in primary sequence. Such 
intramolecular cross-links are frequently located between distinct 
secondary structures, thereby stabilizing the domain tertiary fold. 
While the installation of non-native disulfide bridges has been widely 
applied for the stabilization of tertiary structures, the short distance 
of the resulting cross-link (Cβ–Cβ distance ≤5.5 Å)15 consider-
ably restricts the number of possible modification sites. Seeking to 
overcome this limitation, work dating back to the 1960s has shown 
the use of biselectrophilic reagents to cross-link the amines of two 
lysine side chains, giving access to structurally diverse bridges16–18. 
This approach was used to probe the spatial proximity of lysine 
residues16 and to investigate the effect of intramolecular cross-links 
on protein folding and tertiary structure stability19. Given the high 
abundance of surface lysine residues in proteins and the resulting 
selectivity issues, these macrocyclization reactions were limited to a 
few protein model systems such as ribonuclease A16,17,19.
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Aiming for more general strategies to modify protein chain 
topology, disulfide mimetics have been obtained by cross-link-
ing two reduced cysteine side chains with biselectrophilic agents. 
Examples include the installation of tetrafluorobenzene (1, Fig. 2a) 
for the cross-linking of H2 relaxin20 and the application of oxetane-
based scaffold 2 for the modification of antibody fragments and a 
diphtheria toxin-derived carrier protein21. These biselectrophilic 
agents connect the two cysteine sulfur atoms via a three- or four-
carbon bridge. Depending of the location of the original disulfide, 
the introduction of the organic linker can result in altered protein 
function20. Cysteine-based protein cross-linking approaches have 
also been developed to introduce novel intradomain cross-links. 
For example, a chloroacetamide-modified lysine has been incorpo-
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Fig. 1 | Overview of protein structures and their mimetics. a, Hierarchy of peptide and protein structure, which spans in complexity from primary sequence 
(light blue) to folded secondary structure (blue) and tertiary structure (tan). b, Corresponding hierarchy of peptide and protein mimetics. Peptidomimetics 
encompass agents that recreate primary sequence or isolated secondary structure and can be broadly classified into small molecules, peptides containing 
chemical modification (for example, macrocyclization shown) or artificial backbones with defined folds (‘foldamers’). Proteomimetics, the focus of this 
Perspective, comprise agents that recreate protein tertiary structure and can be classified into molecules with altered chain topology, partially artificial 
backbone compositions or completely artificial backbone compositions. Example peptidomimetic and proteomimetic structures are shown with non-natural 
parts highlighted in red. (Coordinates for structures from: Protein Data Bank (PDB) entries 1A46, 1iJA, 1T3r, 1UBQ, 2AGH, 2QMT, 2YJ1, 2YXJ, 3OXC, 4N5T, 



























































Fig. 2 | examples of proteomimetics based on altered chain topology. a, Overview of bridging moieties including linker structures resulting from reactions 
of biselectrophilic cross-linkers or non-natural amino acids with cysteine (1–4, 7, 8), symmetric trivalent bridges used to cross-link three cysteine residues 
(5, 9) and a linker resulting from a ring-closing metathesis between two modified asparagine residues (6). b, Model of the iNCYPrO-stabilized KiX 
domain based on an NMr structure of the unmodified protein (PDB 2AGH)25. c, NMr structure of a chemically dimerized parallel coiled coil.32 d, NMr 
structure (PDB 5V2G) of the de novo-designed tricyclic three-helix CovCore structure37. Proteins are depicted in cartoon representation with hydrophobic 
core residues shown as sticks (grey). Cross-links are highlighted (red) and shown as sticks.
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domains to capture an appropriately aligned cysteine side chain 
providing thioether linkage 322,23. Broadening the application of this 
strategy to larger proteins, non-canonical mutagenesis was used to 
introduce a tyrosine-derived electrophilic amino acid into a myo-
globin-based cyclopropanation biocatalyst24. The resulting thio-
ether cross-link 4 stabilized the enzyme towards thermal stress and 
high concentrations of organic cosolvent, enabling the cyclopropa-
nation of water-insoluble substrates24. To avoid complications in 
heterologous expression of proteins that result from the use of non-
natural amino acids, two or three solvent-exposed cysteines have 
been introduced and reacted with bis- or triselectrophilic agents 
resulting in the in  situ cyclization of proteins (INCYPRO). The 
most pronounced stabilization effects from the INCYPRO strategy 
were obtained with a triselectrophilic cross-link (5) that resulted 
in bicyclic versions of the transcriptional coactivator domain KIX 
(Fig. 2b) and of the enzyme sortase A25. The stabilized sortase A 
variant was able to catalyse reactions under denaturing conditions. 
Notably, although INCYPRO requires the absence of additional sol-
vent-accessible cysteines, the chemistry tolerates the presence of an 
active-site cysteine in sortase A25.
The selective chemical modification of entire protein domains 
as described above is limited by the inherent selectivity issues when 
addressing natural amino acids. This renders the total chemi-
cal synthesis an appealing alternative strategy, in particular when 
aiming for smaller peptide-derived proteomimetics. Chemical 
synthesis allows the introduction of a broad range of non-natural 
building blocks and topologies, and the application of methodolo-
gies originally developed in the context of classic peptidomimetics. 
In the construction of such synthetic proteomimetics, secondary 
structures such as β-hairpins and α-helices have been utilized as 
assembly units to obtain higher-order folding patterns. A β-hairpin 
comprises two antiparallel β-strands connected by a short loop 
structure. Because hairpins typically exhibit a low folding propen-
sity in isolation, modifications are required to stabilize the fold. 
Most approaches to this end involve macrocyclization either via 
side-chain-to-side-chain bridges or by head-to-tail connections 
using turn-inducing loop structures3,26. Recently, a β-sheet motif 
within a WW domain was stabilized using long polyethyleneglycol-
based cross-linkers (6)27. A noteworthy aspect of that work was the 
finding that relatively long and flexible cross-link architectures can 
efficiently stabilize a complex tertiary structure.
In addition to stabilizing natural tertiary structures, chemical 
cross-links have been applied to link isolated secondary structures 
in nonlinear topologies and facilitate their artificial spatial arrange-
ment into complex protein-like architectures. Early examples 
involve the use of cyclic β-hairpins28 or porphyrins29 as scaffolds for 
the covalent attachment of four helical peptides resulting in folded 
higher-order structures. In later work, natural and de novo-designed 
coiled coils30,31 served as starting point for the design of cross-linked 
helix bundles32–34. Dimeric coiled coils (Fig. 2c) have been stabi-
lized using various linkages such as ethylene glycol (7) and dibenzyl 
ether-based structures (8) installed via biselectrophilic cross-linkers 
and targeting two cysteine side chains32,33. Analogously, cross-linked 
trimeric helix bundles were created, revealing that robust assembly 
relies on carefully designed cross-linkers and supporting interhe-
lical hydrophobic contacts32,34. Hydrophobic bis- and triselectro-
philes, previously used for the generation of mono- and bicyclic 
peptides35,36, have also been utilized to create covalent linkages in 
the hydrophobic core of designed artificial tertiary folds (termed the 
CovCore approach)37. These proteomimetics were de novo designed 
using computational approaches and resulted in structures of high 
thermal stability, as observed for a triangular, head-to-tail cyclized 
three-helix domain arranged around a central 1,3,5-trimethyl 
benzene linker (9) (Fig. 2d)37.
The cross-linking approaches described above implement 
changes in protein topology via the covalent modification of amino 
acid side chains, resulting in permanent structural constraints. 
Alternatively, secondary structure elements, in particular α-helices, 
have been assembled using controllable moieties to devise dynamic 
proteomimetics. A switchable scaffold has been constructed via 
head-to-head ligation of a parallel coiled coil connected by a peptide 
loop containing a binding epitope38. Receptor binding to this epitope 
leads to opening of the coiled-coil structure, which can be detected in 
real time employing an appropriately aligned fluorophore–quencher 
pair. In addition, three-helix assemblies have been templated using 
nucleic acid triplex formation facilitating the dynamic self-assembly 
of protein-like structures39 and highlighting the potential of orthog-
onal self-assembly systems in the design of proteomimetics.
Partially artificial backbones
The canonical l-α-peptide backbone connectivity in proteins is 
not unique in conveying the ability to adopt a protein-like folding 
pattern40–42. Alteration of backbone composition was initially con-
ceived in the context of peptidomimetics, where diverse artificial 
backbones — termed ‘foldamers’43 — have been used to mimic heli-
ces and other isolated segments of protein secondary structure3,5. 
Though primarily applied to generate peptidomimetics, alteration 
of backbone chemical composition also has utility in recreating 
larger, more complex folds and thus proteomimetics. Changing 
the backbone of a protein can have dramatic effects, such as altered 
folding behaviour, molecular recognition, stability to degradation 
and dynamics. Building blocks that have been applied to protein 
backbone modification are diverse in structure (Fig. 3a). Some are 
close structural analogues of native l-α-residues, while others bear 
little resemblance to a natural protein backbone. In addition to 
structural diversity, there is considerable variation in the number 
and density of backbone modifications that have been applied in 
a given chain. Substitution can involve a single amino acid, a con-
tiguous segment of the backbone or the replacement of amino acids 
interspersed throughout a domain.
Pioneering efforts at protein backbone alteration in tertiary 
folds involved single-atom substitution to modulate the forces that 
drive folding and assembly (for example, replacement of a natu-
ral α-residue (10) with an N-Me-α analogue (11))44–49. Later work 
broadened this approach — often referred to as ‘protein prosthe-
sis’ — to encompass more extensive changes to backbone chemi-
cal composition at a single site, with a particular eye to controlling 
conformational preferences at β-turns50–54. The concept of isolated 
prosthetic modification has been leveraged more recently as a strat-
egy to control dynamics in the study of an intrinsically disordered 
sequence through the replacement of one or two α-residues with 
rigidified Cα-methyl analogues (12) in the activation domain from 
the p160 transcriptional co-activator for thyroid hormone and 
retinoid receptors55. Collectively, the above precedents establish 
that backbone connectivity of a natural sequence can be changed 
without abolishing the ability to adopt a complex tertiary fold. An 
important characteristic shared by these examples is that the altered 
backbone connectivity was isolated to one or two sites. Although 
such limited modification can have profound effects, chemists have 
been motivated to produce complex tertiary folds from backbones 
that are more artificial in composition. To this end, a number of 
reports have demonstrated mimicry of prototype proteins by vari-
ants in which an α-helical segment is replaced by a helix mimic. 
In some cases, the prosthetic helix replacement was entirely artifi-
cial in chemical composition. For example, substitution of a helix in 
the chemokine interleukin-8 with a helix composed of β3-residues 
(13)56 and substitution of a helix in the transcription factor hypoxia 
inducible factor-1α with an aromatic oligoamide helix mimetic57 
both led to functional variants of the prototype protein. Related, 
the α-helix in a zinc finger domain was recently replaced by a 
helical oligomer of urea-based residues (14)58. Beyond adopting a 
native-like fold and metal-binding site (Fig. 3b), the chimeric zinc 
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finger domain was able to bind double-stranded DNA. This interac-
tion is driven largely by contacts with the α-helix replaced in the 
prototype, underscoring the effective structural mimicry of this 
portion of the protein by the prosthetic segment.
An alternative approach to prosthetic protein backbone modifi-
cation is to intersperse artificial units alongside natural α-residues 
to replace a local segment of secondary structure in a folded protein 
with a backbone that displays the natural side-chain sequence on 
a partially artificial main chain. An attractive characteristic of this 
approach is that it does not require a priori knowledge of a second-
ary structure mimetic compatible with a given prototype. Instead, 
careful modification enables the biological side-chain sequence to 
recapitulate key non-covalent contacts that drive folding and func-
tion on the newly artificial backbone. Early efforts towards the 
incorporation of locally heterogeneous backbones in protein tertiary 
folds involved replacement of a single secondary structure element. 
Examples of α-helix modifications include transposition of side 
chains from Cα to N in the enzyme ribonuclease A through incorpo-
ration of peptoid residues (15)59 and the introduction of extra back-
bone methylene units in an engineered chorismite mutase through 
α- to β3-residue substitution60. Localized backbone alterations in 
β-sheet-rich folds including β3-residues, N-Me-α-residues and orni-
thine connected via its δ-amine (δ-Orn, 16) have been applied to 
generate bioactive analogues of an antiangiogenic protein fragment61 
and to control the assembly behaviour of amyloidogenic sequences 
(Fig. 3c)62–65. The latter efforts were motivated by a desire to obtain 
fundamental insights into as well as potential inhibitors of amyloid 
formation related to diseases such as Alzheimer’s and Huntington’s. 
Protein domains in which the functionally relevant segment is a sur-
face-exposed loop can also be subject to prosthetic modification, as 
illustrated by the introduction of a flexible spacer in an ion-channel-
inhibitory conotoxin66 and the grafting of an engineered receptor-
binding peptide loop onto a disulfide-rich d-α-residue (17)-based 
knottin scaffold (Fig. 3d)67. In both cases, the modification improved 
stability to degradation by proteolytic enzymes.
The above examples illustrate that backbone alterations can be 
accommodated in any of the common secondary structures, but can 
such changes be applied globally? Answering this question requires 
consideration of two key challenges. The first relates to monomer 
selection. Because different backbones are predisposed to stabilize 
different local folds, it is difficult to create a proteomimetic con-
sisting of an array of different secondary structures based on just a 
single α-residue replacement type. The second challenge relates to 
the plasticity of natural side-chain sequences with respect to func-
tioning on backbones of altered composition. In many of the exam-
ples cited above, backbone modifications made to an isolated part 
of a protein had a small unfavourable effect on fold stability and/or 
function. This is not surprising, as the sequences being mimicked 
did not evolve to function on the types of employed backbones. 
Despite these challenges, substantial progress has been made in 
generating proteomimetics from more densely modified backbones.
One of the first examples to apply systematic backbone modi-
fication throughout a tertiary structure entailed the mimicry of 
a small, phage-derived peptide inhibitor of vascular endothelial 
growth factor signalling with an ordered but irregular folding pat-
tern68. Substitution of selected α-residues in the native sequence 
with a combination of β3-residues and cyclic β-residue 18 led to 
an analogue that showed an improvement in stability to degrada-
tion by protease enzymes, albeit at the expense of a modest loss in 
receptor affinity. Moving towards mimicry of more complex folds 
required the application of a wider assortment of α-residue replace-
ments. An early illustration of this is seen in the development of 
heterogeneous-backbone variants of the B1 domain of streptococ-
cal protein G (GB1), which contains helix, sheet, turn and loop 
secondary structures and is stabilized by a well-packed hydro-
phobic core69. The key to successful recreation of the GB1 tertiary 
fold was to employ a variety of different backbone modification 
types (for example, d-α-, N-Me-α-, Cα-Me-α- and β3-residues, 
as well as cyclic β-residue 19 and cyclic γ-residue 20). Subsequent 
work on the GB1 system yielded a set of general design 
principles for the application of diverse building block types in the 
construction of heterogeneous-backbone proteomimetics70. These 
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Fig. 3 | examples of proteomimetics based on partially artificial backbone compositions. a, Chemical structures of selected residue types used to 
construct modified protein backbones. b–g, Experimentally determined folded structures of modified-backbone proteomimetics. Native l-α-residues are 
shown in grey and non-natural monomers in red. Each panel is labelled with the domain mimicked and a list of residue types in the chain. b, NMr structure 
of a zinc finger domain mimic with an artificial helix (PDB 5N14)58. c, Crystal structure of a trimeric assembly formed by a sequence derived from amyloid 
β (Aβ) with turn-inducing and sheet-disrupting modifications (PDB 4NTr)94. d, NMr structure of a knottin mimic with a heterochiral backbone comprising 
a d-α-peptide core and native loop67. e, NMr structure of a zinc finger domain mimic with backbone modifications in the helix and hairpin regions  
(PDB 5US3)71. f, Crystal structure of a helix–turn–helix scaffold modified in the helices (PDB 4WPB)72 . g, NMr structure of a de novo disulfide-rich  
scaffold harbouring modifications throughout the helix, loop, turn and sheet (PDB 6E5J)74.
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Aiming for the reproduction of a zinc finger, it was found that 
some heterogeneous-backbone variants of the prototype containing 
a combination of β3- and N-Me-α-residues exhibited higher ther-
modynamic folded stability than the natural backbone (Fig. 3e)71. 
This was a noteworthy result in illustrating that a biologically 
derived side-chain sequence can fold more favourably on a hetero-
geneous backbone. This study also highlights challenges in devel-
oping proteomimetics based on heterogeneous backbones, as a 
metal-binding β-turn in the prototype proved completely intolerant 
to a number of backbone alterations known to effectively stabilize 
turns in other contexts. The ability to mimic isolated helical second-
ary structures with heterogeneous backbones has been leveraged to 
produce mimics of a bioactive helix–turn–helix tertiary scaffold in 
which the helices incorporate a combination of Cα-Me-α-, β3- and 
cyclic β-residues (Fig. 3f)72. Noteworthy here was the observation 
that receptor affinities of the variants were in some cases indistin-
guishable from the natural-backbone prototype. The functional 
potential of heterogeneous-backbone proteomimetics was further 
highlighted by a recent report of artificial variants of the protein 
ubiquitin that are able to engage in native multi-protein signalling 
pathways73. De novo-designed tertiary structures have also served 
as inspiration for the design of proteomimetics, as shown by the 
backbone modification of a computationally designed disulfide-
rich scaffold to yield mimetics with identical folds and increased 
proteolytic stability (Fig. 3g)74.
Completely artificial backbones
The design of proteomimetics based on completely artificial back-
bones is a particularly challenging endeavour as it requires the 
de novo design of a side-chain sequence able to specify a tertiary 
fold, and at the same time a backbone capable of manifesting the 
sequence-encoded fold. Notably, the resulting architectures, unhin-
dered by natural constraints of protein-like folding patterns, offer 
the prospect of functions beyond those known from natural sys-
tems. Pioneering efforts that paved the way towards completely 
artificial proteomimetics involved a range of oligamide-based 
foldamers capable of adopting robust secondary structures40–42,75. 
While these molecules were inspired to some degree by biomac-
romolecules, many of the resulting folds depart considerably from 
nature, complicating their use for the creation of tertiary folding 
patterns. The difficulties associated with the design of completely 
artificial proteomimetics explain the smaller number of mimetics 
compared with the two categories discussed above. Already existing 
examples, however, highlight the potential of complex architectures 
that lack analogous prototypes in nature.
Early efforts towards complex folded structures composed 
entirely of artificial monomer units entailed the design of amphiphi-
lic helices that assemble into defined helix bundles. Examples with 
folded structures characterized at high resolution include an oligo-
mer of β3-residues (13) that forms an octameric bundle (Fig. 4a)76  
and an oligomer of urea-based monomers (14) that forms a hex-
americ assembly (Fig. 4b)77. Both these systems are formally an 
example of quaternary structure as each consists of an assembly 
of isolated secondary structure elements. Nevertheless, these 
prototypes were later advanced to create analogous helix-bundle 
assemblies with complex functions, including small-molecule rec-
ognition78, catalysis79,80 and metal binding81. The first examples 
towards unimolecular tertiary structure from completely artifi-
cial backbones involved the creation of helix–turn–helix motifs 
by a design analogous to that of abovementioned helix bundles82. 
Results here were encouraging, although the proposed tertiary 
structures were not confirmed by X-ray crystallography or NMR.
Oligoamides based on rigid aromatic building blocks (for exam-
ple, 21–29, Fig. 4c) have proven to be a particularly robust platform 
for creating complex folding patterns. A sophisticated example of a 
corresponding unimolecular folding motif is the helical molecular 
capsule that lacks an analogous architecture in natural proteins. 
Patterning aromatic amide building blocks of differing length, 
geometry and composition along a helical chain yielded a defined 
internal pocket that could selectively bind a monosaccharide guest 
(Fig. 4d)83. Notably, this architecture is formally at the level of 
secondary structure; however, it is able to accomplish a function 
(molecular encapsulation) that in a protein would require a higher-
order tertiary fold. Design principles towards aromatic oligoamides 
have been advanced more recently to construct true tertiary folds 
comprising multiple secondary structures arrayed in a single 
entirely artificial chain. Corresponding helix–turn–helix (Fig. 4e)84 
and helix–sheet–helix motifs85, as well as multi-stranded sheets86 
have been designed and characterized at atomic resolution. Most 
noteworthy, the helix–turn–helix system displays cooperativity in 
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Fig. 4 | examples of proteomimetics based on entirely artificial backbone 
compositions. a,b, Crystal structures of an octameric helix bundle 
assembly formed by a β3-peptide (a)76 and a hexameric helix bundle 
assembly formed by an urea oligomer (b)77; structures are coloured by 
chain. c, Chemical structures of monomers used in the construction of 
aromatic oligoamide foldamers. d, Crystal structure of fructose (yellow) in 
complex with an aromatic oligoamide helical capsule83. e, Crystal structure 
of an aromatic oligoamide helix–turn–helix motif84.
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Conclusions and future directions
The unique folding properties and functions of proteins have stimu-
lated diverse efforts to understand these phenomena at the molecu-
lar level, and to mimic or improve certain protein features. Initially, 
small protein fragments were the focus of such work, resulting 
in a multitude of approaches towards peptidomimetic agents. 
Recently, there has been an increasing interest in the mimicry of 
larger more complex folds resulting in tertiary structure mimet-
ics, which we term proteomimetics herein. These efforts have been 
mainly motivated by basic questions regarding protein-folding 
and -recognition processes as well as the design of high-affinity 
ligands or artificial agents with enzymatic activity. The past has 
seen the emergence of novel mimicry approaches that have often 
been applied individually, but more recent results show a trend 
towards the use of different approaches in combination. Notably, 
while proteomimetic approaches in the past have predominantly 
focused on the characterization of folding properties of the result-
ing molecules, current efforts appear to focus more on their use 
as biomimetic agents, highly selective binders or catalysts. In addi-
tion, recent advances in allied fields will enable the more efficient 
development and construction of proteomimetics. For example, 
one can expect that the number of biocompatible reactions used 
for the construction of proteomimetics will continuously increase, 
and that computational de novo protein design will give access to 
entirely novel proteomimetic scaffolds. Regarding efforts towards 
development of proteomimetics as bio-inspired catalysts, the rap-
idly evolving field of artificial metalloenzymes88,89 will provide a 
rich source of inspiration. Notably, covalently modified proteins 
have already been evolved by using metal-coordinating non-nat-
ural amino acids90–92 or artificial post-translational modification93. 
Proteomimetic approaches may be diverse, but scientists working 
in this area are united by a shared curiosity about protein function 
and the search for artificial substitutes. The emerging field of pro-
teomimetics research promises to benefit from this diversity and 
lead to important advances that address central questions associ-
ated with human health and a more sustainable society.
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